PARP抑制剂在非BRCA DNA修复异常mCRPC中的疗效:PROfound试验B队列预设终点重建
该分析重建了PROfound试验B队列(12种非BRCA同源重组修复基因异常)的患者水平数据。奥拉帕利组54例中2例(4%)和对照组24例中2例(8%)出现影像学缓解,无证据表明奥拉帕利延长影像学无进展生存(HR 0.88,95%CI 0.58-1.34),与A队列形成强烈对比。
要点
- B队列奥拉帕利影像学缓解率4%(2/54),对照组8%(2/24)。
- B队列奥拉帕利未显著延长影像学无进展生存(HR 0.88,95%CI 0.58-1.34)。
- 非BRCA DNA修复异常患者从奥拉帕利获益可能甚微,与BRCA异常者不同。
核心结论
- 在非BRCA同源重组修复基因异常的mCRPC患者中,奥拉帕利的影像学缓解率和影像学无进展生存获益与BRCA1/2及ATM异常患者形成强烈对比。
研究设计与样本
- 基于III期PROfound试验(奥拉帕利 vs 对照)的B队列患者水平数据重建分析,B队列涉及12种非BRCA同源重组修复基因异常。
主要发现
- B队列奥拉帕利组54例中2例(4%)出现影像学缓解,对照组24例中2例(8%)出现影像学缓解。
- B队列奥拉帕利未延长影像学无进展生存(HR 0.88,95%CI 0.58-1.34)。
关键数值与推荐
- B队列影像学缓解率:奥拉帕利组4%(2/54),对照组8%(2/24)。
- B队列影像学无进展生存:HR 0.88,95%CI 0.58-1.34。
临床怎么用
- 对携带非BRCA同源重组修复基因异常的mCRPC患者,应审慎评估奥拉帕利获益,避免类比BRCA异常患者的疗效。
局限性
- B队列样本量小(奥拉帕利组54例,对照组24例),结果解读需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The PROfound trial evaluated the PARP inhibitor olaparib in metastatic castration-resistant prostate cancers harboring alterations in BRCA1/2 and ATM (cohort A) and in 12 other homologous recombination repair genes (cohort B). Olaparib led to more objective responses and longer radiographic progression-free survival than the control in cohort A and when cohorts A and B were combined. The efficacy of olaparib in cohort B was a secondary objective prespecified in the trial protocol but was not reported. Reconstructing patient-level data for cohort B, two of 54 patients (4%) in the olaparib arm and two of 24 patients (8%) in the control arm had a radiographic response, and there was no evidence that olaparib prolonged radiographic progression-free survival in cohort B (hazard ratio 0.88, 95% confidence interval 0.58-1.34). These results are in strong contrast to cohort A. PATIENT SUMMARY: A large clinical study concluded that treatment with the PARP inhibitor olaparib benefits men with metastatic castration-resistant prostate cancer whose tumors harbor alterations in 15 different DNA repair genes. In contrast to the group dominated by BRCA alterations, any potential benefit from olaparib was considerably less, if present at all, for men with prostate cancers harboring one of the 12 other, non-BRCA DNA repair alterations.
引用
- Stopsack KH. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. 2020. PMID: 33012578. doi:10.1016/j.eururo.2020.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。